Mifegyne

Mifepristone, the active ingredient in Mifegyne, is a progesterone receptor antagonist presented as an oral formulation for oral use. It is employed for the medical termination of intrauterine pregnancy up to ten weeks and for the management of early pregnancy loss.

GNH USA supplies Mifegyne as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use.

Mifegyne, a progesterone receptor antagonist, is used in early pregnancy management and medical abortion protocols.

- Medical termination of intrauterine pregnancy up to 10 weeks: induces abortion in early pregnancy. - Management of early pregnancy loss: promotes expulsion of retained products of conception. - Adjunct to misoprostol in medical abortion protocols: enhances efficacy of prostaglandin‑mediated uterine evacuation.

Mifegyne may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Abdominal cramping - Vaginal bleeding

Serious or Rare Side Effects: - Heavy hemorrhage requiring medical intervention - Severe infection (sepsis) - Allergic reaction or anaphylaxis

When prescribing Mifegyne, clinicians should observe several safety measures to minimize risk.

- Confirm gestational age: ensure pregnancy is ≤10 weeks. - Obtain baseline labs: hemoglobin, blood type, and Rh status. - Screen for contraindications: chronic adrenal insufficiency, long‑term corticosteroid therapy, or anticoagulant use. - Provide counseling on follow‑up: schedule ultrasound verification of complete evacuation. - Avoid use in ectopic pregnancy: contraindicated if ectopic gestation is suspected. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Mifegyne can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Concurrent use of CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy. - Co‑administration with anticoagulants may increase bleeding risk.

Moderate Interactions (Monitor Closely): - Use with NSAIDs may increase gastrointestinal discomfort. - Combination with hormonal contraceptives does not affect efficacy but counseling is recommended. - Timing with misoprostol is essential for optimal regimen success.